D.L. Gregory¹, C.D. Jones², E.R.E. Denton³ and A.N. Harnett⁴

¹Department of Oncology, Addenbrookes Hospital, Cambridge, UK. ²Department of Ophthalmology, Norfolk and Norwich University Hospital Norwich, UK. ³Department of Radiology, Norfolk and Norwich University Hospital Norwich, UK. ⁴Department of Oncology, Norfolk and Norwich University Hospital Norwich, UK.

Abstract

We present a case of a female patient who developed acute onset of visual loss due to central serous retinopathy as a consequence of steroid premedication for docetaxol given as second line neoadjuvant chemotherapy for breast cancer. Central serous retinopathy is a recognised association with steroids but has not been previously reported in association with the management of solid tumours. Reduction in steroid dose and duration permitted recovery of her visual acuity while allowing completion of the prescribed chemotherapy regimen. An overview of the presentation, pathogenesis, aetiologies and management of central serous retinopathy is given.